Skip Nav Destination

Issue Archive

Select Year

Issue

INSIDE BLOOD ADVANCES

Diagnosing TMAs by automated red cell morphology analyses

Henny H. Billett,Morayma Reyes Gil

View Articletitled, Diagnosing TMAs by automated red cell morphology analyses

More evidence for low-dose IL-2 for chronic GVHD in children
Clinical Trials & Observations

John E. Levine

View Articletitled, More evidence for low-dose IL-2 for chronic GVHD in children

DRUG ADVANCES

Olutasidenib: from bench to bedside
Clinical Trials & Observations

Sangeetha Venugopal,Justin Watts

View Articletitled, Olutasidenib: from bench to bedside

REVIEW ARTICLES

Telomerase-targeted therapies in myeloid malignancies

Julian A. Waksal,Claudia Bruedigam,Rami S. Komrokji,Catriona H. M. Jamieson,John O. Mascarenhas

View Articletitled, Telomerase-targeted therapies in myeloid malignancies

Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes

Eduard Schulz,Peter D. Aplan,Sylvie D. Freeman,Steven Z. Pavletic

View Articletitled, Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes

Supplemental data

Tetraspanins set the stage for bone marrow microenvironment–induced chemoprotection in hematologic malignancies

Anthony Quagliano,Anilkumar Gopalakrishnapillai,Sonali P. Barwe

View Articletitled, Tetraspanins set the stage for bone marrow microenvironment–induced chemoprotection in hematologic malignancies

CLINICAL TRIALS AND OBSERVATIONS

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
Clinical Trials & Observations

View Articletitled, Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
Clinical Trials & Observations

View Articletitled, Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Supplemental data

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Clinical Trials & Observations

View Articletitled, Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Supplemental data

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
Clinical Trials & Observations

View Articletitled, Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial

Supplemental data

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
Clinical Trials & Observations

Betty K. Hamilton,Lisa A. Rybicki,Hong Li,Taylor Lucas,Donna Corrigan,Matt Kalaycio,Ronald Sobecks,Rabi Hanna,Seth J. Rotz,Robert M. Dean,Aaron T. Gerds,Deepa Jagadeesh,Claudio Brunstein,Craig S. Sauter,Edward A. Copelan,Navneet S. Majhail

View Articletitled, Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention

Supplemental data

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
Clinical Trials & Observations

Tycel J. Phillips,David Bond,Radihka Takiar,Karson Kump,Malalthi Kandarpa,Philip Boonstra,Tera Lynn Mayer,Victoria Nachar,Ryan A. Wilcox,Shannon A. Carty,Yasmin H. Karimi,Zaneta Nikolovska-Coleska,Mark S. Kaminski,Alex F. Herrera,Kami Maddocks,Leslie Popplewell,Alexey V. Danilov

View Articletitled, Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma

Supplemental data

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Clinical Trials & Observations

Jad Othman,Charlotte Wilhelm-Benartzi,Richard Dillon,Steve Knapper,Sylvie D. Freeman,Leona M. Batten,Joanna Canham,Emily L. Hinson,Julie Wych,Sophie Betteridge,William Villiers,Michelle Kleeman,Amanda Gilkes,Nicola Potter,Ulrik Malthe Overgaard,Priyanka Mehta,Panagiotis Kottaridis,Jamie Cavenagh,Claire Hemmaway,Claire Arnold,Mike Dennis,Nigel H. Russell,on behalf of the UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group

View Articletitled, A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Supplemental data

Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant
Clinical Trials & Observations

Allison L. Bartlett,Grace Zhang,Gregory Wallace,Stacie McLean,Kasiani C. Myers,Ashley Teusink-Cross,Cynthia Taggart,Bhaumik Patel,Robert Davidson,Stella M. Davies,Sonata Jodele

View Articletitled, Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant

HEALTH SERVICES AND OUTCOMES

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia

Lindsey E. Roeker,Maral DerSarkissian,Kellie Ryan,Yan Chen,Mei Sheng Duh,Svea K. Wahlstrom,Shweta Hakre,Louise Yu,Helen Guo,Anthony R. Mato

View Articletitled, Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia

Supplemental data

Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report

View Articletitled, Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report

Supplemental data

HEMATOPOIESIS AND STEM CELLS

Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes

Sergiu Pasca,Matthew Z. Guo,Shiyu Wang,Kristin Stokvis,Audra Shedeck,Aparna Pallavajjala,Cynthia Shams,Roshni Pallavajjala,Amy E. DeZern,Ravi Varadhan,Christopher D. Gocke,Richard J. Jones,Lukasz P. Gondek

View Articletitled, Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb

Vaishnavi Rajagopal,Nina Leksa,Ronald Gorham,Siddharth Jindal,Soumya Nair,Kevin Knockenhauer,Joanne Chan,Tony Byun,Courtney Mercadante,Stephen Moore,Sandip Panicker,Graham Parry,Michael Storek

View Articletitled, SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb

Supplemental data

CD38 as a pan-hematologic target for chimeric antigen receptor T cells

Tina Glisovic-Aplenc,Caroline Diorio,John A. Chukinas,Kimberly Veliz,Olga Shestova,Feng Shen,Selene Nunez-Cruz,Tiffaney L. Vincent,Fei Miao,Michael C. Milone,Carl H. June,David T. Teachey,Sarah K. Tasian,Richard Aplenc,Saar Gill

View Articletitled, CD38 as a pan-hematologic target for chimeric antigen receptor T cells

Supplemental data

Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires

View Articletitled, Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires

Supplemental data

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

Erin A. Dean,Gregory J. Kimmel,Matthew J. Frank,Ali Bukhari,Nasheed M. Hossain,Michael D. Jain,Saurabh Dahiya,David B. Miklos,Philipp M. Altrock,Frederick L. Locke

View Articletitled, Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease
Clinical Trials & Observations

Holly Wobma,Malika Kapadia,Haesook T. Kim,Francesca Alvarez-Calderon,Susanne H. C. Baumeister,Christine Duncan,Suzanne Forrest,Lev Gorfinkel,Jennifer Huang,Leslie E. Lehmann,Hojun Li,Marc Schwartz,John Koreth,Jerome Ritz,Leslie S. Kean,Jennifer S. Whangbo

View Articletitled, Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease

Supplemental data

More evidence for low-dose IL-2 for chronic GVHD in children
Clinical Trials & Observations

John E. Levine

View Articletitled, More evidence for low-dose IL-2 for chronic GVHD in children

LYMPHOID NEOPLASIA

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

View Articletitled, Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

Supplemental data

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

View Articletitled, Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

Supplemental data

Identification of USP9X as a leukemia susceptibility gene
Clinical Trials & Observations

Saumya Dushyant Sisoudiya,Pamela Mishra,He Li,Jeremy M. Schraw,Michael E. Scheurer,Sejal Salvi,Harsha Doddapaneni,Donna Muzny,Danielle Mitchell,Olga Taylor,Aniko Sabo,Philip J. Lupo,Sharon E. Plon

View Articletitled, Identification of USP9X as a leukemia susceptibility gene

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

Diego Villa,Aixiang Jiang,Carlo Visco,Nicola Crosbie,Rory McCulloch,Michael J. Buege,Anita Kumar,David A. Bond,Jonas Paludo,Matthew J. Maurer,Gita Thanarajasingam,Katharine L. Lewis,Chan Y. Cheah,Joachim Baech,Tarec C. El-Galaly,Laveniya Kugathasan,David W. Scott,Alina S. Gerrie,David Lewis

View Articletitled, Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

Supplemental data

Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging

Kyle T. Wright,Jason L. Weirather,Sizun Jiang,Katrina Z. Kao,Yari Sigal,Anita Giobbie-Hurder,Margaret A. Shipp,Scott J. Rodig

View Articletitled, Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging

Supplemental data

MYELOID NEOPLASIA

Genomic landscape of TP53-mutated myeloid malignancies

View Articletitled, Genomic landscape of TP53-mutated myeloid malignancies

Supplemental data

PLATELETS AND THROMBOPOIESIS

Individual phosphatidylinositol transfer proteins have distinct functions that do not involve lipid transfer activity

Liang Zhao,Chelsea L. Thorsheim,Aae Suzuki,Timothy J. Stalker,Sang H. Min,Sriram Krishnaswamy,Shamshad Cockcroft,Karen E. Anderson,Brittany Weiderhold,Charles S. Abrams

View Articletitled, Individual phosphatidylinositol transfer proteins have distinct functions that do not involve lipid transfer activity

Supplemental data

Characterization of the human platelet N- and O-glycome upon storage using tandem mass spectrometry

Katelyn E. Rosenbalm,Melissa M. Lee-Sundlov,David J. Ashline,Renata Grozovsky,Kazuhiro Aoki,Andrew J. S. Hanneman,Karin M. Hoffmeister

View Articletitled, Characterization of the human platelet N- and O-glycome upon storage using tandem mass spectrometry

Supplemental data

Ontogenesis of functional platelet subpopulations from preterm and term neonates to adulthood: The PLINIUS study

Lukas J. Weiss,Maria Drayss,Kristina Mott,Sarah Beck,David Unsin,Bastian Just,Christian P. Speer,Christoph Härtel,Oliver Andres,Harald Schulze

View Articletitled, Ontogenesis of functional platelet subpopulations from preterm and term neonates to adulthood: The PLINIUS study

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Computer vision quantitation of erythrocyte shape abnormalities provides diagnostic, prognostic, and mechanistic insight

Brody H. Foy,Jonathan A. Stefely,Pavan K. Bendapudi,Robert P. Hasserjian,Hanny Al-Samkari,Abner Louissaint, Jr.,Megan J. Fitzpatrick,Bailey Hutchison,Christopher Mow,Julia Collins,Hasmukh R. Patel,Chhaya H. Patel,Nikita Patel,Samantha N. Ho,Richard M. Kaufman,Walter H. Dzik,John M. Higgins,Robert S. Makar

View Articletitled, Computer vision quantitation of erythrocyte shape abnormalities provides diagnostic, prognostic, and mechanistic insight

Supplemental data

Diagnosing TMAs by automated red cell morphology analyses

Henny H. Billett,Morayma Reyes Gil

View Articletitled, Diagnosing TMAs by automated red cell morphology analyses

THROMBOSIS AND HEMOSTASIS

Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents
Clinical Trials & Observations

Dana Egan-Sherry,Philip Grosse,James D. Cooper

View Articletitled, Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents

TRANSPLANTATION

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
Clinical Trials & Observations

Federica R. Achini-Gutzwiller,Marco W. Schilham,Erik G. J. von Asmuth,Anja M. Jansen-Hoogendijk,Cornelia M. Jol-van der Zijde,Maarten J. D. van Tol,Robbert G. M. Bredius,Tayfun Güngör,Arjan C. Lankester,Dirk Jan A. R. Moes

View Articletitled, Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study

Supplemental data

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
Clinical Trials & Observations

View Articletitled, Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

Supplemental data

RESEARCH LETTERS

Longitudinal metabolic study of red blood cells from patients undergoing gender-affirming testosterone therapy
Clinical Trials & Observations

Micaela Kalani Roy,Rebecca Burgoyne Wilkerson,Keisha Alexander,Natalie J. Nokoff,Melanie Cree-Green,Angelo D’Alessandro

View Articletitled, Longitudinal metabolic study of red blood cells from patients undergoing gender-affirming testosterone therapy

Supplemental data

Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia
Clinical Trials & Observations

Angela Rankine-Mullings,Russell Keenan,Subarna Chakravorty,Baba Inusa,Paul Telfer,Mark Velangi,Russell E. Ware,Jon J. Moss,Adam L. Lloyd,Sarah Edwards,Hussain Mulla

View Articletitled, Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia

Supplemental data

Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis

Riccardo Masetti,Francesco Baccelli,Davide Leardini,Francesca Gottardi,Francesca Vendemini,Alessandro Di Gangi,Marco Becilli,Mariachiara Lodi,Manuela Tumino,Luca Vinci,Miriam Erlacher,Brigitte Strahm,Charlotte M. Niemeyer,Franco Locatelli

View Articletitled, Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis

Supplemental data

Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis

Sharmila Raghunandan,Lev Gorfinkel,Michael Graiser,Brandi Bratrude,Yvonne Suessmuth,Scott Gillespie,Adrianna Lynn Westbrook,Kirsten M. Williams,Michelle L. Schoettler,Leslie S. Kean,John Horan,Amelia A. Langston,Muna Qayed,Benjamin Watkins

View Articletitled, Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis

In-person and virtual assessment of short physical performance battery test in older adults with myeloid malignancies
Clinical Trials & Observations

Chandrika Sanapala,Marielle Jensen-Battaglia,Erin E. Watson,Sravani Konatham,Marissa LoCastro,Ying Wang,Eva Culakova,Michael Sohn,Marie Flannery,Allison Magnuson,Tanya M. Wildes,Kah Poh Loh

View Articletitled, In-person and virtual assessment of short physical performance battery test in older adults with myeloid malignancies

Supplemental data

“Autoimmune HIT” antibodies in diagnostic samples are a potential artifact and not associated with more severe outcomes

Adam J. Kanack,Janhavi Athale,Rachel R. Leger,Abdul Saadalla,Nahla M. Heikal,Dong Chen,David A. Garcia,Ravinder Singh,Rajiv K. Pruthi,Anand Padmanabhan

View Articletitled, “Autoimmune HIT” antibodies in diagnostic samples are a potential artifact and not associated with more severe outcomes

Supplemental data

Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy

Mariam T. Nawas,Annie Im,Brian Shaffer

View Articletitled, Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy

Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models

Elisa ten Hacken,Shanye Yin,Robert Redd,María Hernández Sánchez,Kendell Clement,Gabriela Brunsting Hoffmann,Fara F. Regis,Elizabeth Witten,Shuqiang Li,Donna Neuberg,Luca Pinello,Kenneth J. Livak,Catherine J. Wu

View Articletitled, Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models

Supplemental data

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

Bhavana Bhatnagar,Jessica Kohlschmidt,Shelley J. Orwick,Daelynn R. Buelow,Sydney Fobare,Christopher C. Oakes,Jonathan E. Kolitz,Geoff Uy,Wendy Stock,Bayard L. Powell,Deedra Nicolet,Erin K. Hertlein,Krzysztof Mrózek,James S. Blachly,Ann-Kathrin Eisfeld,Sharyn D. Baker,John C. Byrd

View Articletitled, Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

Supplemental data

COMMENTARIES

Use of letermovir in umbilical cord blood transplantation based on risk scores

Monica M. Rivera Franco,Hanadi Rafii,Fernanda Volt,Chantal Kenzey,Barbara Cappelli,Graziana Maria Scigliuolo,Vanderson Rocha,Nicole Raus,Jean-Hugues Dalle,Patrice Chevallier,Marie Robin,Marie Thérèse Rubio,Annalisa Ruggeri,Eliane Gluckman,on behalf of Eurocord and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

View Articletitled, Use of letermovir in umbilical cord blood transplantation based on risk scores

Identifying experts for clinical practice guidelines: perspectives from the ASH Guideline Oversight Subcommittee

Michael Byrne,Ryan Mattison,Rachel Bercovitz,Richard Lottenberg,Suely M. Rezende,Roy Silverstein,Deirdra Terrell,Rob Kunkle,Deion Smith,Catherine Bollard,Sandra Haberichter,Jennifer Holter-Chakrabarty,Menaka Pai,Matthew Cheung,Adam Cuker,Matthew Seftel,Benjamin Djulbegovic

View Articletitled, Identifying experts for clinical practice guidelines: perspectives from the ASH Guideline Oversight Subcommittee

CNL and aCML are prognostically distinct: a large National Cancer Database analysis

Douglas Tremblay,Dahniel Sastow,John Mascarenhas

View Articletitled, CNL and aCML are prognostically distinct: a large National Cancer Database analysis

How I read an article that uses machine learning methods

Aziz Nazha,Olivier Elemento,Shannon McWeeney,Moses Miles,Torsten Haferlach,on behalf of the American Society of Hematology Artificial Intelligence Taskforce

View Articletitled, How I read an article that uses machine learning methods

ERRATA

Mazzara S, Travaini L, Botta F, et al. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL. Blood Adv. 2023;7(4):630-643.

View Articletitled, Mazzara S, Travaini L, Botta F, et al. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL. Blood Adv. 2023;7(4):630-643.

Supplemental data

Greenwood M, Trahair T, Sutton R, et al. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Adv. 2021;5(24):5574-5583.

View Articletitled, Greenwood M, Trahair T, Sutton R, et al. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Adv. 2021;5(24):5574-5583.

Supplemental data

Cover Image

Cover Image

Tetraspanin domain organization and function. Tetraspanins are characterized by 4 transmembrane domains (labeled 1-4) that, together with the palmitoylation sites (green triangles), are crucial for the formation of tetraspanin-enriched microdomains. The disulfide-stabilized variable region of the large extracellular loop adjoins the conserved region, which mediates homodimerization. The C terminus interacts with signaling and cytoskeletal proteins. See the article by Quagliano et al.
Front Matter
Editorial Board

Issue Archive

Table of Contents

INSIDE BLOOD ADVANCES

More evidence for low-dose IL-2 for chronic GVHD in children Clinical Trials & Observations

DRUG ADVANCES

Olutasidenib: from bench to bedside Clinical Trials & Observations

REVIEW ARTICLES

CLINICAL TRIALS AND OBSERVATIONS

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma Clinical Trials & Observations

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study Clinical Trials & Observations

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study Clinical Trials & Observations

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial Clinical Trials & Observations

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention Clinical Trials & Observations

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma Clinical Trials & Observations

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial Clinical Trials & Observations

Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant Clinical Trials & Observations

HEALTH SERVICES AND OUTCOMES

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease Clinical Trials & Observations

More evidence for low-dose IL-2 for chronic GVHD in children Clinical Trials & Observations

LYMPHOID NEOPLASIA

Identification of USP9X as a leukemia susceptibility gene Clinical Trials & Observations

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents Clinical Trials & Observations

TRANSPLANTATION

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study Clinical Trials & Observations

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD Clinical Trials & Observations

RESEARCH LETTERS

Longitudinal metabolic study of red blood cells from patients undergoing gender-affirming testosterone therapy Clinical Trials & Observations

Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia Clinical Trials & Observations

In-person and virtual assessment of short physical performance battery test in older adults with myeloid malignancies Clinical Trials & Observations

COMMENTARIES

ERRATA

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

More evidence for low-dose IL-2 for chronic GVHD in children
Clinical Trials & Observations

Olutasidenib: from bench to bedside
Clinical Trials & Observations

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
Clinical Trials & Observations

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
Clinical Trials & Observations

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
Clinical Trials & Observations

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
Clinical Trials & Observations

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
Clinical Trials & Observations

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
Clinical Trials & Observations

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Clinical Trials & Observations

Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant
Clinical Trials & Observations

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease
Clinical Trials & Observations

More evidence for low-dose IL-2 for chronic GVHD in children
Clinical Trials & Observations

Identification of USP9X as a leukemia susceptibility gene
Clinical Trials & Observations

Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents
Clinical Trials & Observations

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
Clinical Trials & Observations

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
Clinical Trials & Observations

Longitudinal metabolic study of red blood cells from patients undergoing gender-affirming testosterone therapy
Clinical Trials & Observations

Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia
Clinical Trials & Observations

In-person and virtual assessment of short physical performance battery test in older adults with myeloid malignancies
Clinical Trials & Observations